Abstract：Objective To systematically assess the efficacy and safety of eltrombopag in the treatment of children with immune thrombocytopenia (ITP). Methods PubMed, Embase, Cochrane Library, Weipu Data, CNKI, and Wanfang Data were searched for studies on eltrombopag used for the treatment of children with ITP. RevMan 5.3 and R version 3.6 were used to perform a Meta analysis of included studies. Results A total of 11 studies were included, with 2 randomized controlled trials and 9 cohort studies. The Meta analysis of the 9 cohort studies showed that eltrombopag had a response rate of about 70% (95%CI: 65%-76%) in the treatment of children with ITP, with no serious adverse events. The Meta analysis of the randomized controlled trials showed that the eltrombopag group had a higher response rate than the placebo group (RR=2.64, 95%CI: 1.58-4.44, P<0.05), while there was no significant difference in the incidence rates of adverse events and serious adverse events between the two groups (P>0.05). Conclusions Eltrombopag has good efficacy and safety as a second-line treatment regimen for children with ITP.
XU Jin-Yun,WANG Yong,WU Yong et al. Safety and efficacy of eltrombopag in the treatment of children with immune thrombocytopenia: a Meta analysis[J]. CJCP, 2021, 23(9): 944-950.
